Literature DB >> 31543255

Medication-Assisted Treatment for Opioid-Use Disorder.

Tyler S Oesterle1, Nuria J Thusius2, Teresa A Rummans3, Mark S Gold4.   

Abstract

The United States is in the midst of a national opioid epidemic. Physicians are encouraged both to prevent and treat opioid-use disorders (OUDs). Although there are 3 Food and Drug Administration-approved medications to treat OUD (methadone, buprenorphine, and naltrexone) and there is ample evidence of their efficacy, they are not used as often as they should. We provide a brief review of the 3 primary medications used in the treatment of OUD. Using data from available medical literature, we synthesize existing knowledge and provide a framework for how to determine the optimal approach for outpatient management of OUD with medication-assisted treatments.
Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31543255     DOI: 10.1016/j.mayocp.2019.03.029

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  14 in total

Review 1.  New directions in the treatment of opioid withdrawal.

Authors:  A Benjamin Srivastava; John J Mariani; Frances R Levin
Journal:  Lancet       Date:  2020-06-20       Impact factor: 79.321

2.  Medical Detoxification for Nonopioid Substances is Associated With Lower Likelihood of Subsequent Linkage to Substance Use Disorder Treatment.

Authors:  Laura MacKinnon; JinCheol Choi; Mary Clare Kennedy; Rupinder Brar; M-J Milloy; Kanna Hayashi; Maria Eugenia Socías
Journal:  J Addict Med       Date:  2022-03-01       Impact factor: 4.647

3.  Demographic and Clinical Correlates of Treatment Completion among Older Adults with Heroin and Prescription Opioid Use Disorders.

Authors:  Namkee G Choi; Diana M DiNitto; C Nathan Marti; Bryan Y Choi
Journal:  J Psychoactive Drugs       Date:  2021-11-25

Review 4.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

5.  Persons who inject drugs (PWID) retain functional NK cells, dendritic cell stimulation, and adaptive immune recall responses despite prolonged opioid use.

Authors:  Costin Tomescu; Krystal Colon; Peter Smith; Mack Taylor; Livio Azzoni; David S Metzger; Luis J Montaner
Journal:  J Leukoc Biol       Date:  2020-12-02       Impact factor: 6.011

6.  Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice.

Authors:  Mark Deyo-Svendsen; Matthew Cabrera Svendsen; James Walker; Andrea Hodges; Rachel Oldfather; Meghna P Mansukhani
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec

7.  Molecular neuro-biological and systemic health benefits of achieving dopamine homeostasis in the face of a catastrophic pandemic (COVID- 19): A mechanistic exploration.

Authors:  B W Downs; K Blum; D Bagchi; S Kushner; M Bagchi; J M Galvin; McG Lewis; D Siwicki; R Brewer; B Boyett; D Baron; J Giordano; R D Badgaiyan
Journal:  J Syst Integr Neurosci       Date:  2020-04-30

Review 8.  Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?

Authors:  Mark S Gold; David Baron; Abdalla Bowirrat; Kenneth Blum
Journal:  J Neurol Sci       Date:  2020-09-15       Impact factor: 3.181

9.  A Molecularly Imprinted Sol-Gel Electrochemical Sensor for Naloxone Determination.

Authors:  Narges Shaabani; Nora W C Chan; Abebaw B Jemere
Journal:  Nanomaterials (Basel)       Date:  2021-03-03       Impact factor: 5.076

Review 10.  A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration.

Authors:  Kenneth Blum; Shan Kazmi; Edward J Modestino; Bill William Downs; Debasis Bagchi; David Baron; Thomas McLaughlin; Richard Green; Rehan Jalali; Panayotis K Thanos; Igor Elman; Rajendra D Badgaiyan; Abdalla Bowirrat; Mark S Gold
Journal:  J Pers Med       Date:  2021-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.